CN108464996A - A kind of targeting adjusts pharmaceutical composition and its application of gene - Google Patents
A kind of targeting adjusts pharmaceutical composition and its application of gene Download PDFInfo
- Publication number
- CN108464996A CN108464996A CN201810402041.1A CN201810402041A CN108464996A CN 108464996 A CN108464996 A CN 108464996A CN 201810402041 A CN201810402041 A CN 201810402041A CN 108464996 A CN108464996 A CN 108464996A
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- extract
- present
- gene
- parts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
- A61K36/04—Rhodophycota or rhodophyta (red algae), e.g. Porphyra
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
- A61K36/428—Trichosanthes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Alternative & Traditional Medicine (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Inorganic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to pharmaceutical composition and its applications that a kind of targeting adjusts gene, belong to technical field of drug development.Pharmaceutical composition provided by the invention includes seaweed extract, Snakegourd Fruit seed extract, kudzu root extract and mineral element replenishers；The mineral element includes zinc and magnesium.The drug that pharmaceutical composition provided by the invention is prepared can target the expression that LHPP, ZBTB20 and ALDH2 gene is turned up simultaneously, inhibit the proliferation of liver cancer cells, realize the treatment of liver cancer, and have good dispelling effects of alcohol.
Description
Technical field
The present invention relates to technical field of drug development, and in particular to it is a kind of targeting adjust gene pharmaceutical composition and its
Using.
Background technology
Hepatopathy is to threaten the important diseases of world population health.In this killer family of cancer, onset of liver cancer rate occupies complete
Ball second.Virus hepatitis, aflatoxin, the chemical carcinogen based on N- nitroso compounds, heavy metal deposition,
Gene mutation, overnutrition (macronutrient) or nutritional deficiency (such as vitamin A, B1 lack), hemochromatosis, parasitic infection
And the risk factor of heredity, long term alcohol intake etc. and induced hepatocellular carcinoma.China hepatopath is numerous, only Chronic Hepatitis B
Just have 20,000,000, every year because of dead nearly 500,000 people of hepatopathy.Hepatic sclerosis is higher in China's incidence.Liver cancer as cancer kind occurred frequently, by
Fast in its incidence of occult, progression of disease, the prognosis of patient is extremely pessimistic, and new accurate diagnosis and treatment and intervention are extremely urgent.
Invention content
The purpose of the present invention is to provide pharmaceutical composition and its applications that a kind of targeting adjusts gene.The present invention provides
The drug that is prepared of pharmaceutical composition can target the expression that LHPP, ZBTB20 and ALDH2 gene is turned up simultaneously, inhibit
The proliferation of liver cancer cells realizes the treatment of liver cancer, and has good dispelling effects of alcohol.
The present invention provides the pharmaceutical compositions that a kind of targeting adjusts gene, including the extraction of seaweed extract, Chinese Drug Gualouzi
Object, kudzu root extract and mineral element replenishers；The mineral element includes zinc and magnesium.
Preferably, described pharmaceutical composition includes the component of following mass fraction：25~150 parts of seaweed extract, melon
10~40 parts of 50~200 parts of beach wormwood seed extract, 25~200 parts of kudzu root extract and mineral matter element replenishers.
Preferably, the ratio of the zinc and magnesium is (1~20)：(1~300).
Preferably, the seaweed extract includes the ethanesulfonic acid that mass concentration is 0.3~1%.
Preferably, the Snakegourd Fruit seed extract includes the glyceride that mass concentration is 1~10%.
Preferably, the kudzu root extract includes the Puerarin that mass fraction is 5~40%.
The present invention also provides above-mentioned technical proposal described pharmaceutical composition prepare target be turned up LHPP, ZBTB20 and
Application in ALDH2 gene expression drugs.
Preferably, the drug includes the drug for preventing or treating liver cancer.
The present invention also provides application of the above-mentioned technical proposal described pharmaceutical composition in preparing antialcoholic drugs.
The present invention provides the pharmaceutical compositions that a kind of targeting adjusts gene.It is prepared by pharmaceutical composition provided by the invention
Obtained drug can target the expression that LHPP, ZBTB20 and ALDH2 gene is turned up simultaneously, inhibit the proliferation of liver cancer cells, real
The treatment of existing liver cancer；It can accelerate the decomposition rate to acetaldehyde by the raising of the content of ALDH2 genes, realize the work(to relieve the effect of alcohol
Can, there is good dispelling effects of alcohol.
Specific implementation mode
The present invention provides the pharmaceutical compositions that a kind of targeting adjusts gene, including the extraction of seaweed extract, Chinese Drug Gualouzi
Object, kudzu root extract and mineral element replenishers；The mineral element includes zinc and magnesium.
In the present invention, described pharmaceutical composition includes the component of following mass fraction：25~150 parts of seaweed extract,
10~40 parts of 50~200 parts of Snakegourd Fruit seed extract, 25~200 parts of kudzu root extract and mineral matter element replenishers.
Pharmaceutical composition of the present invention includes 25~150 parts of seaweed extract, preferably 50~100 parts, more preferably
It is 85 parts.The present invention does not have special restriction to the preparation method of the seaweed extract, using known to those skilled in the art
Seaweed extract extracting method, specifically, seaweed extract of the present invention preferably entrusts the gloomy not natural system in Shaanxi
Product Co., Ltd prepares, and the seaweed extract public prepared by Shaanxi Sen Fu natural products Co., Ltd can also obtain.
In the present invention, the seaweed extract include mass concentration be 0.3~1% ethanesulfonic acid, more preferably 0.5~0.8%.This
Seaweed extract of the invention rich in ethanesulfonic acid can influence the expression activity of LHPP, increase the expression of LHPP.Seaweed of the present invention
The higher zinc ion of abundance and amino acid also contribute to the synthesis and expression of ZBTB20 zinc finger proteins in extract.
Pharmaceutical composition of the present invention includes 50~200 parts of Snakegourd Fruit seed extract, preferably 100~180 parts, more
Preferably 160 parts.The present invention does not have special restriction to the preparation method of the Snakegourd Fruit seed extract, using art technology
The extracting method of Snakegourd Fruit seed extract known to personnel, specifically, Snakegourd Fruit seed extract of the present invention preferably entrust Shan
Xi Senfu natural products Co., Ltd prepares, and Snakegourd Fruit seed extract prepared by Shaanxi Sen Fu natural products Co., Ltd is public
Crowd can also obtain.In the present invention, the Snakegourd Fruit seed extract includes the glyceride that mass concentration is 1~10%, more preferably
It is 3~8%.Snakegourd Fruit seed extract of the present invention rich in glyceride can influence the expression activity of LHPP, increase the table of LHPP
It reaches.
Pharmaceutical composition of the present invention includes 25~200 parts of kudzu root extract, preferably 100~180 parts, more excellent
It is selected as 165 parts.The present invention does not have the preparation method of the kudzu root extract special restriction, using those skilled in the art
The extracting method of well known kudzu root extract, specifically, kudzu root extract of the present invention preferably entrust the gloomy not day in Shaanxi
Right Products Co., Ltd prepares, and the kudzu root extract public prepared by Shaanxi Sen Fu natural products Co., Ltd can also obtain
.In the present invention, the kudzu root extract include mass fraction be 5~40% puerarin derivate, more preferably 15~
30%.Kudzu root extract of the present invention rich in puerarin derivate ((2- ethoxys) -1- piperazines) can influence the table of LHPP
Up to activity, increase the expression of LHPP.It in the present invention, also can be by adding Puerarin to improve the concentration of puerarin derivate
The commercially available pharmaceutical preparation of derivative is realized.
Liver is communicated by hepatic portal and choleresis system with enteron aisle.To the macro genome of intestinal flora studies have shown that
Relative to the intestinal flora of healthy control group, patient with liver cirrhosis group intestinal flora is leading, and Pseudomonas --- Bacteroides is in hepatic sclerosis
Group content significantly reduces.Veillonella, streptococcus, Clostridium and general the Bordetella content in liver cirrhosis group
Increase.In the level of kind, increased most 20 kinds of liver cirrhosis group content, 4 belong to streptococcus, and 6 belong to Wei Rongqiu
Pseudomonas.And in some patient with liver cirrhosis enteron aisles it is more some be typically found in the germ in oral cavity.These harmful enterobacteriaceaes
Belong to, is that carcinogenic toxins in liver is caused to input important source without stop and the solid refractory major reason of hepatopathy object for appreciation.This hair
The stigmastene in flavone compound daidzein active constituent and Snakegourd Fruit seed extract in the bright kudzu root extract
Alcohol active constituent has significant bacteriostasis to Coccus, Escherichia coli, Song's interior trim shigella dysenteriae, proteus etc., can
Harmful intestinal tract flora is cut off to input the virogeny of liver from vena portae hepatica and choleresis system.In addition, of the present invention
Fucoidin active constituent in seaweed extract also has to DPPH free radicals, hydroxyl radical free radical Scavenging activity, and can increase
The activity of strong iron reducing power realizes the inhibition for microenvironment of growing up to liver cancer cells.
Pharmaceutical composition of the present invention includes 10~40 parts of mineral element replenishers, preferably 15~30 parts, more excellent
It is selected as 20 parts.In the present invention, the mineral element includes zinc and magnesium；In the mineral element ratio of zinc and magnesium be (1~
20)：(1~300), more preferably (3~12)：(10~150).In the present invention, the Zn-ef ficiency is preferably derived from sulfuric acid
One kind in zinc, zinc gluconate, glycine zine, zinc oxide, zinc lactate, zinc citrate, zinc chloride, zinc acetate and zinc carbonate
Or it is a variety of.In the present invention, the Zn-ef ficiency is conducive to the conjunction of ZBTB20 zinc finger proteins as the ion with targeting
At and expression activity, sufficient zinc ion can ensure that ZBTB20 gene biologicals component is not distorted by toxic heavy metal ion,
In the present invention, a sequence-specific transcription repressor of the Zinc finger protein ZBTB20 as a-fetoprotein gene (AFP) be
Regulate and control the key molecule of alpha-fetoprotein gene expression, the synthesis of ZBTB20 zinc finger proteins and active guarantee, to turning to alpha-fetoprotein
Record plays inhibiting effect.Alpha-fetoprotein (AFP) is a kind of glycoprotein, belongs to albumin family, has many important physiology work(
Can, including transportation function, the two-way regulating function as growth regulator, immunosupress, T lymphocytes be apoptosis-induced etc..
Alpha-fetoprotein and the occurrence and development of liver cancer and kinds of tumors are closely related, and higher concentration is can express out in kinds of tumors,
It can be used as the positive detection index of kinds of tumors.
In the present invention, the magnesium elements are preferably derived from magnesium sulfate, magnesium chloride, magnesia, magnesium carbonate, magnesium monohydrogen phosphate
With it is one or more in magnesium gluconate.Magnesium ion of the present invention can be directly affected as prothetic group activated metal ion
The expression activity of LHPP and its important collateral line HDHD2.
The present invention by magnesium ion, the seaweed extract rich in ethanesulfonic acid, the Snakegourd Fruit seed extract rich in glyceride, contain
The puerarin derivate of ethoxy-piperazine structure is combined, and can dramatically increase LHPP expression.Increase LHPP gene expressions
It then can effectively inhibit cancer cell multiplication and prevent liver dysfunction；Lack whole phosphorylation caused by LHPP to increase, it is likely that
Activation has the access (including mTOR signal paths) of critical function, leads to cancer.
The Zn that zinc sulfate in compsn. consisting of influenza virus surface of the present invention is provided2+And high abundance in seaweed extract
Zn2+、Mg2+、Mn2+, niacinamide and its synthesis precursor tryptophan, iodate pyrazoles polysaccharide structures, it is sweet in Snakegourd Fruit seed extract
Grease and arginine guanidine radicals structure, the ketone group structure of kudzu root extract provide for the synthesis and dehydrogenation activation of mitochondria ALDH2
Biologic component can promote the height-regulating of ALDH2.
The present invention does not have the preparation method of described pharmaceutical composition special restriction, by each extract and replenishers letter
Single mixing.
The present invention also provides above-mentioned technical proposal described pharmaceutical composition prepare target be turned up LHPP, ZBTB20 and
Application in ALDH2 gene expression drugs.In the present invention, the drug preferably includes to prevent or treat liver-cancer medicine.This hair
The bright dosage form to the drug does not have special restriction, such as oral using pharmaceutical dosage form well known to those skilled in the art
Liquid formulation, capsule preparations etc..In the present invention, when the dosage form of described pharmaceutical composition is oral liquid formulations, pharmaceutical composition
Mass percent in oral solution is preferably 30~50%, and more preferably 40%；When the dosage form of described pharmaceutical composition is glue
When capsule, mass percentage of the pharmaceutical composition in capsule is preferably 80~90%, and more preferably 85%.The present invention is in institute
When stating pharmaceutical composition and being prepared into specific dosage form, auxiliary material is preferably added, the application does not have the type of the auxiliary material special limit
It is fixed, using the corresponding customary adjuvant of corresponding dosage form.When the dosage form of described pharmaceutical composition is oral solution, the auxiliary material
Preferably include glycerine, phosphoric acid, sucrose, taurine and peppermint oil；It is described auxiliary when the dosage form of described pharmaceutical composition is capsule
Material preferably includes hydroxymethyl starch and syrup.The present invention does not have the additive amount of the auxiliary material special restriction, using described auxiliary
Expect the conventional additive amount in oral solution or capsule preparations.
The present invention also provides application of the above-mentioned technical proposal described pharmaceutical composition in preparing antialcoholic drugs.This hair
The bright dosage form to the drug does not have special restriction, such as oral using pharmaceutical dosage form well known to those skilled in the art
Liquid formulation, capsule preparations etc..In the present invention, when the dosage form of described pharmaceutical composition is oral liquid formulations, pharmaceutical composition
Mass percent in oral solution is preferably 30~50%, and more preferably 40%；When the dosage form of described pharmaceutical composition is glue
When capsule, mass percentage of the pharmaceutical composition in capsule is preferably 80~90%, and more preferably 85%.The present invention is in institute
When stating pharmaceutical composition and being prepared into specific dosage form, auxiliary material is preferably added, it is special that the application does not have the type of the auxiliary material
It limits, using the corresponding customary adjuvant of corresponding dosage form.It is described auxiliary when the dosage form of described pharmaceutical composition is oral solution
Material preferably includes glycerine, phosphoric acid, sucrose, taurine and peppermint oil；It is described when the dosage form of described pharmaceutical composition is capsule
Auxiliary material preferably includes hydroxymethyl starch and syrup.The present invention does not have the additive amount of the auxiliary material special restriction, using described
Conventional additive amount of the auxiliary material in oral solution or capsule preparations.
Most murder by poisoning of drinking both is from oxidation product --- the acetaldehyde in ethyl alcohol in vivo.Acetaldehyde can lead to DNA double
Chain is broken, and leads to chromosomal rearrangement, and for good and all change DNA sequence dna.Acetaldehyde dehydrogenase (ALDH2) enzyme can be by acetal dehyde decomposition
At the acetate of nonhazardous, the metabolism of one of the energy source as cell is fallen, this is also the heat place of wine.It is catalyzed in ALDH2
In the individual of inactive forms, the increase of acetaldehyde contact may assign the neurological susceptibility to multiple types cancer bigger.There is research aobvious
Show, Ethanol intake is related with the onset risk raising of 7 kinds of cancers, and which includes the cancers occurred frequently such as liver cancer, the cancer of the esophagus.
ALDH2 genes are zinc enzymes, in biologic component, contain 4 iodo- pyrazoles and nicotinoyl amine structure.
The Zn that zinc sulfate in compsn. consisting of influenza virus surface of the present invention is provided2+And high abundance in seaweed extract
Zn2+、Mg2+、Mn2+, niacinamide and its synthesis precursor tryptophan, iodate pyrazoles polysaccharide structures, it is sweet in Snakegourd Fruit seed extract
Grease and arginine guanidine radicals structure, the ketone group structure of kudzu root extract provide for the synthesis and dehydrogenation activation of mitochondria ALDH2
The raising of biologic component, ALDH2 contents can accelerate the decomposition rate to acetaldehyde, realize the function of relieving the effect of alcohol.
Pharmaceutical composition provided by the invention includes Zn-ef ficiency, magnesium elements, seaweed extract, Snakegourd Fruit seed extract and Pueraria lobota
The combination of root extract, the active constituent of above-mentioned composition can increase LHPP, ZBTB20, ALDH2 gene expression, phase simultaneously
The expression of gene any than single height-regulating LHPP, ZBTB20, ALDH2 improves 30% to effective control drop conspicuousness of alpha-fetoprotein
More than.
With reference to specific embodiment to it is of the present invention it is a kind of targeting adjust gene pharmaceutical composition and its application
It is further described in detail, technical scheme of the present invention includes but not limited to following embodiment.
Embodiment 1
A kind of targeting adjusts the drug composition oral liquid formulation of gene
The active component and content of the oral liquid formulations are as shown in table 1, auxiliary material be glycerine, phosphoric acid, sucrose, taurine,
Blueberry juice and peppermint oil.
1 drug composition oral liquid ingredient of table
Embodiment 2
A kind of targeting adjusts the drug composition oral liquid formulation of gene
The component and content of the oral liquid formulations are as shown in table 2 below, and auxiliary material is glycerine, phosphoric acid, sucrose, taurine, indigo plant
Certain kind of berries fruit juice and peppermint oil.
2 drug composition oral liquid component of table
| Element | Per the content of 100mL solution |
| Kudzu root extract | 1.5g |
| Seaweed extract | 1.5g |
| Snakegourd Fruit seed extract | 1.5g |
| Zinc | 12mg |
| Magnesium | 300mg |
| Glycerine | 10~30mg |
| Phosphoric acid | 10~30mg |
| Sucrose | 1~5g |
| Taurine | 10~20mg |
| Blueberry juice | 5~10g |
| Peppermint oil | 1~5mg |
Embodiment 3
A kind of compsn. consisting of influenza virus surface capsule is calculated per granule product 350mg, component and content such as table 3, and auxiliary material is carboxylic first
Base sodium starch, blueberry powder and syrup.
3 medicament composition capsule component of table
Embodiment 4
With the cooperations such as Shenzhen target gene research and development centre, the healthy medical inspection mechanism in Shenzhen first, to Guangdong, Anhui, perfume (or spice)
The tissue samples of 25 patients with hepatocellular carcinoma in the ground such as port and themselves non-cancer tissue sample are compared, and find cancerous tissue
In LHPP, ZBTB20, ALDH2 level significantly decline, agree to by patient and family members, take the embodiment of the present invention 1
Experimental formula carries out intervention in 10 days by a definite date respectively, then carries out control test, it is found that the LHPP levels in cancerous tissue are average
Rise 60% or more；The indexs mean reduction such as alpha-fetoprotein reaches 30%.Wherein, alpha-fetoprotein (AFP) reaches 30000ng/
5 patients of mL have 3 indexs to drop to 1500ng/mL or less levels, have 2 indexs to drop to 10000ng/mL or less water
It is flat.
Embodiment 5
In December, 2017 in March, 2018, Wuhan favour group target gene, Shenzhen target gene, which are combined, convenes more than 500 people
The volunteer of scale carries out acetaldehyde-dehydrogenase enzyme activition to patented product of the present invention and relieves the effect of alcohol verification, and 95% or more volunteer is anti-
Feedback drinks high spirit after drinking this patent formula oral solution 30 minutes, and capacity for liquor obviously rises, and after 1 hour, has rapid
Awake sense, feels untired for second day, liver does not have abnormal response.Having 200 people, often trial edition patent formulation is oral repeatedly
Liquid,
To March, it is real that Wuhan Center for Disease Control carries out acute liver to patented product of the present invention within 2 months 2018
It tests.
Using Kunming mouse, it is divided into Normal group, model control group (8.3mL/ low with pharmaceutical composition of the present invention
KgBW (16.6mL/kgBW) in), high (25.0mL/kgBW) dosage group, the disposable gavage of each group mouse give tested material, and 30
Chmice acute alcoholism model is established with 50% gavage 16mL/kg.BW of (V/V) ethyl alcohol after minute, observes and records mouse
Drunk incubation period, drunk rate, sober up the time, for 24 hours the interior death rate；24th hour non-dead animal, 3% yellow Jackets (100
~80mg/kg) abdominal aorta is taken a blood sample after intraperitoneal injection of anesthesia, measure serum AST, ALT, TG, alcohol dehydrogenase, acetaldehyde-dehydrogenase
Enzymatic activity puts to death animal, partial liver is taken, for liver histopathological analysis.
The result shows that the present composition rate of relieving the effect of alcohol reaches 86%.
TG (10% liver homogenate acetaldehyde) serum content numerical value comparison is as follows：
Control class mean is 0.36mmol/L；Model class mean is 1.23mmol/L；Experimental group (pharmaceutical composition of the present invention
Object middle dosage intervene after) mean value be 1.09mmol/L.(P ＜ 0.05-0.01)
ALDH liver content numerical value comparisons are as follows：
It is 9.358 to compare class mean；Model class mean is 14.493；(pharmaceutical composition middle dosage of the present invention is dry for experimental group
Prognosis) mean value be 17.178.(P ＜ 0.05-0.01).
The above is only a preferred embodiment of the present invention, it is noted that for the ordinary skill people of the art
For member, various improvements and modifications may be made without departing from the principle of the present invention, these improvements and modifications
It should be regarded as protection scope of the present invention.
Claims (9)
1. a kind of targeting adjusts the pharmaceutical composition of gene, which is characterized in that including seaweed extract, Snakegourd Fruit seed extract, Pueraria lobota
Root extract and mineral element replenishers；The mineral element includes zinc and magnesium.
2. pharmaceutical composition according to claim 1, which is characterized in that described pharmaceutical composition includes following mass fraction
Component：25~150 parts of seaweed extract, 50~200 parts of Snakegourd Fruit seed extract, 25~200 parts of kudzu root extract and minerals
10~40 parts of component extender.
3. pharmaceutical composition according to claim 1 or 2, which is characterized in that the ratio of the zinc and magnesium is (1~20)：
(1~300).
4. pharmaceutical composition according to claim 1 or 2, which is characterized in that the seaweed extract includes mass concentration
For 0.3~1% ethanesulfonic acid.
5. pharmaceutical composition according to claim 1 or 2, which is characterized in that the Snakegourd Fruit seed extract includes that quality is dense
The glyceride that degree is 1~10%.
6. pharmaceutical composition according to claim 1 or 2, which is characterized in that the kudzu root extract includes mass fraction
For 5~40% Puerarin.
7. claim 1~6 any one described pharmaceutical composition is preparing targeting height-regulating LHPP, ZBTB20 and ALDH2 gene
Express the application in drug.
8. application according to claim 7, which is characterized in that the drug includes the drug for preventing or treating liver cancer.
9. application of the claim 1~6 any one described pharmaceutical composition in preparing antialcoholic drugs.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810402041.1A CN108464996A (en) | 2018-04-28 | 2018-04-28 | A kind of targeting adjusts pharmaceutical composition and its application of gene |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810402041.1A CN108464996A (en) | 2018-04-28 | 2018-04-28 | A kind of targeting adjusts pharmaceutical composition and its application of gene |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108464996A true CN108464996A (en) | 2018-08-31 |
Family
ID=63263774
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810402041.1A Pending CN108464996A (en) | 2018-04-28 | 2018-04-28 | A kind of targeting adjusts pharmaceutical composition and its application of gene |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108464996A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114794016A (en) * | 2022-05-09 | 2022-07-29 | 承葛生物技术(广州)有限公司 | Method for constructing intestinal flora distribution disorder and anti-tumor immunity disorder model |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1602758A (en) * | 2004-11-10 | 2005-04-06 | 李祥麟 | Nutritious liquor (drink) for relieving the effect of alcohol, alcohol relieving capsule production method |
| CN103211957A (en) * | 2013-05-02 | 2013-07-24 | 赵月 | Alcohol relieving and liver protecting composition and application thereof |
| CN103478838A (en) * | 2013-09-25 | 2014-01-01 | 湖北省宏源药业有限公司 | Honeysuckle kudzuvine root beverage and preparation method thereof |
| US20140011887A1 (en) * | 2003-11-19 | 2014-01-09 | Obio Pharmaceutical (H.K.) Limited | Materials and methods for improving alcohol metabolism and alleviating the effects of hangovers |
-
2018
- 2018-04-28 CN CN201810402041.1A patent/CN108464996A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140011887A1 (en) * | 2003-11-19 | 2014-01-09 | Obio Pharmaceutical (H.K.) Limited | Materials and methods for improving alcohol metabolism and alleviating the effects of hangovers |
| CN1602758A (en) * | 2004-11-10 | 2005-04-06 | 李祥麟 | Nutritious liquor (drink) for relieving the effect of alcohol, alcohol relieving capsule production method |
| CN103211957A (en) * | 2013-05-02 | 2013-07-24 | 赵月 | Alcohol relieving and liver protecting composition and application thereof |
| CN103478838A (en) * | 2013-09-25 | 2014-01-01 | 湖北省宏源药业有限公司 | Honeysuckle kudzuvine root beverage and preparation method thereof |
Non-Patent Citations (3)
| Title |
|---|
| 南朝君: "《食疗 营养与烹调》", 31 January 2014, 中国医药科技出版社 * |
| 国家药典委员会: "《中华人民共和国药典临床用药须知：2015年版.中药饮片卷》", 30 September 2017, 中国医药科技出版社 * |
| 田心: "《跑赢高血压》", 31 January 2015, 吉林科学技术出版社 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114794016A (en) * | 2022-05-09 | 2022-07-29 | 承葛生物技术(广州)有限公司 | Method for constructing intestinal flora distribution disorder and anti-tumor immunity disorder model |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Yokozawa et al. | Role of ginsenoside-Rd in cisplatin-induced renal injury: special reference to DNA fragmentation | |
| TWI538680B (en) | Side effects of combinations of chemotherapy drugs to slow things | |
| EP2077851A1 (en) | A pharmaceutical composition comprising cordycepin for the treatment and prevention of obesity | |
| Luo et al. | Monofloral triadica cochinchinensis honey polyphenols improve alcohol-induced liver disease by regulating the gut microbiota of mice | |
| Kageyama et al. | Anti-tumor and anti-metastasis activities of honey bee larvae powder by suppressing the expression of EZH2 | |
| Jiao et al. | Metabonomics and the gut microbiome analysis of the effect of 6-shogaol on improving obesity | |
| KR20070105486A (en) | Tea and tea manufacturing method for improving liver function and curing of hangover | |
| Zhao et al. | Probiotic‐fermented Pueraria lobata (Willd.) Ohwi alleviates alcoholic liver injury by enhancing antioxidant defense and modulating gut microbiota | |
| Zhu et al. | Capparis spinosa Alleviates DSS‐Induced Ulcerative Colitis via Regulation of the Gut Microbiota and Oxidative Stress | |
| KR20100059302A (en) | Compositions for skin external application containing extracts of hisbiscior cortex | |
| CN116676240B (en) | Lactobacillus rhamnosus and application thereof in preventing or treating alcoholic liver disease | |
| Li et al. | Polysaccharides from Panax ginseng CA Meyer alleviated DSS-induced IBD by inhibiting JAK2/STAT1/NLPR3 inflammasome signalling pathway in mice | |
| CN108464996A (en) | A kind of targeting adjusts pharmaceutical composition and its application of gene | |
| CN111635844A (en) | Method for preparing highland barley compound wine with function of improving anoxia tolerance | |
| Sun et al. | Dietary supplementation with polysaccharides from Rhizoma dioscoreae resulting in the enhanced immunity and the structural modulation of the intestinal microbiota in Luciobarbus capito | |
| KR20200081553A (en) | Composition for the prevention and improvement of Antitussive and Expectorant | |
| CN113151371B (en) | Probiotic extracellular polysaccharide, preparation method and anti-tumor application thereof | |
| CN113908169B (en) | Pharmaceutical composition and application thereof | |
| Wei et al. | Synergistic protection of combined Aronia melanocarpa Elliot anthocyanins with aloe polysaccharides inhibits alcoholic liver injury in mice | |
| Wang et al. | Very-light alcohol consumption suppresses breast tumor progression in a mouse model | |
| Lu et al. | Protective effects of puerarin on liver tissue in Salmonella-infected chicks: a proteomic analysis | |
| CN110123824B (en) | Ilicis Pubescentis saponin A1New use of | |
| CN107007610B (en) | Application of benzophenone compound in pharmacy | |
| Liu et al. | Theaflavins mitigate diabetic symptoms in GK rats by modulating the INSR/PI3K-Akt/GSK-3 pathway and intestinal microbiota | |
| Li et al. | Effects of traditional Chinese herbal medicines on egg production, egg quality and antioxidant enzyme activities in aged laying hens |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180831 |